

Aug 21, 2020

ELISA for quantification of IL-35 in human serum.

DOI

dx.doi.org/10.17504/protocols.io.bj37kqrn

Angel A Justiz-Vaillant¹

¹University of the West Indies St. Augustine

University of the West In...

angel.vaillant@sta.uwi.e...



Angel A Justiz-Vaillant

University of the West Indies St. Augustine

OPEN  ACCESS



DOI: dx.doi.org/10.17504/protocols.io.bj37kqrn

Protocol Citation: Angel A Justiz-Vaillant 2020. ELISA for quantification of IL-35 in human serum.. **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.bj37kqrn>

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: In development

We are still developing and optimizing this protocol

Created: August 21, 2020

Last Modified: August 21, 2020

Protocol Integer ID: 40799



Abstract

Interleukins (IL) are a type of cytokine first thought to be expressed by leukocytes alone but have later been found to be produced by many other body cells. They play essential roles in the activation and differentiation of immune cells, as well as proliferation, maturation, migration, and adhesion. They also have pro-inflammatory and anti-inflammatory properties. The primary function of interleukins is, therefore, to modulate growth, differentiation, and activation during inflammatory and immune responses. Interleukins consist of a large group of proteins that can elicit many reactions in cells and tissues by binding to high-affinity receptors in cell surfaces.

Regulatory B cells mainly secrete IL-35. One of the primary functions of this interleukin is its involvement in lymphocyte differentiation. It exhibits an immune-suppressive effect. [\[1\]](#)

Reference

1. Justiz Vaillant AA, Qurie A. Interleukin. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; June 12, 2019.

- 1 An anti-human IL-35 coating antibody is adsorbed onto the microwells by incubation overnight at 4°C with carbonate-bicarbonate buffer.
- 2 Add 50 µl of human serum. Human IL-35 present in the serum sample binds to antibodies adsorbed into the microwells.
- 3 The microplate is blocked with 3% non-fat milk-PBS buffer and later wash to remove unbound proteins.
- 4 Fifty (50) µl of biotin-conjugated anti-human IL-35 antibody is added. The optimal dilution must be investigated.
- 5 The microplate is rewashed with PBS-Tween 20 buffer, pH 7.4.
- 6 One hundred µl of streptavidin-HRP conjugate is added and it binds to the biotin-conjugated anti-human IL-35 antibody. The optimal dilution of this conjugate must be investigated.
- 7 The plate is washed following incubation to remove the unbound Streptavidin-HRP.
- 8 Add 100 µl of 3',3',5',5' - tetramethylbenzidine (TMB; Sigma-Aldrich) into each well.
- 9 Incubate the microwells in the dark for 15 min.
- 10 A colored product is formed in proportion to the quantity of human IL-35 present in the sample or standard.
- 11 The reaction is terminated by addition of 100 µl 3M H₂SO₄ and the absorbance is measured at 450 nm.
- 12 A standard curve is made from 7 human IL-35 standard dilutions and the human IL-35 sample concentration is determined.



- 13 For better results place the microplate on a microplate shaker in every incubation.